HOME ABOUT US ADVERTISE SUBSCRIBE SITE MAP HELP CONTACT WORK FOR US  
Friday
3 September 2010
Make BTN my HomePage 
 




Revenue Matters: GTG, AtCor, Heartware and more
Thursday, 29 July 2010
Amanda Ellis

FOLLOWING its acquisition of the Brevagen breast cancer risk test, Genetic Technologies has increased its takings by 89% to 3.3 million.


You are not logged in or not authorised to view this page.

Get Your FREE 30 Day Trial Now!

First Name
Last Name
Phone
Email Address
Confirm Email

OR

Members Login Here

Email Address
Password
 

  • Note: Cookies must be enabled to log in
  • Forgotten Your Password? Click here
  • Having problems? View our help page here.

Click here to read the rest of today's news stories.